ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
46 announcements with these filters
RPG Life Sciences convened its 19th Annual General Meeting for July 23, 2026. Key agenda items include declaring a Rs.24 per share dividend and adopting financial statements.
RPG Life Sciences Ltd has submitted its Annual Report for FY 2025-2026. The filing includes the Business Responsibility and Sustainability Report.
RPG Life Sciences cancels the inadvertently set record date for dividend eligibility. The corrected record date will be announced after the AGM.
RPG Life Sciences clarified that the recent surge in trading volume has no underlying unpublished event. The increase is attributed solely to market conditions.
RPG Life Sciences notified shareholders regarding the mandatory transfer of unclaimed dividends and shares to the IEPF. Shareholders must claim dues by September 01, 2026.
RPG Life Sciences reports 8.3% YoY revenue growth to ₹707.5 cr in FY26, driven by domestic formulations outperforming the market by 1.6x.
RPG Life Sciences Limited reported its FY26 results, with annual standalone total income of ₹733.06 Crore and net profit of ₹115.17 Crore. The Board recommended a dividend of ₹24 per share (300%). Additionally, Dr. Pratit Samdani was appointed as an Additional Independent Director for a five-year term.
RPG Life Sciences delivered strong Q4 FY26 performance with 23.6% revenue growth and 58.1% PAT growth (excl. exceptions), driven by Domestic Formulations and margin expansion.
RPG Life Sciences Limited appointed Dr. Pratit Samdani as a Non-Executive Independent Director for a five-month term effective April 29, 2026. Dr. Samdani is a highly respected physician with over two decades of experience in Internal Medicine and Critical Care.
RPG Life Sciences Limited has recommended a final dividend of 300% per equity share for the period ended April 2026. The record date and general meeting date for shareholder approval are yet to be fixed. This follows a board meeting concluded on April 29, 2026.
RPG Life Sciences reported a 23.6% Y-o-Y revenue increase to ₹176.9 Crore for Q4 FY26, with an EBITDA margin of 25.6%. Full-year FY26 revenue grew 8.3% to ₹707.5 Crore. The Board recommended a 300% dividend (₹24 per share). Growth was driven by robust performance in Domestic Formulations and a strong recovery in the API division.
RPG Life Sciences Ltd reported revenue from operations of ₹176.9 Cr (+23.6% YoY) and net profit of ₹29.9 Cr (-74.5% YoY) for Q4 FY26.
RPG Life Sciences Limited reported a standalone total income of ₹733.06 Crore for the year ended March 31, 2026. The Board recommended a dividend of ₹24 (300%) per equity share and appointed Dr. Pratit Samdani as an Additional Non-Executive Independent Director for five years.
Clarus Capital I acquired 1,45,113 shares (0.88% stake) of RPG Life Sciences Limited via the open market on April 17, 2026. This acquisition increased its total holding from 4.53% to 5.41%, crossing the 5% disclosure threshold under SEBI SAST Regulations.
RPG Life Sciences Ltd reported net profit of ₹22.1 Cr (-36.7% YoY) for Q3 FY26.
RPG Life Sciences Limited has launched the 'Saksham Niveshak' 100-day campaign, following IEPFA guidelines. The initiative encourages shareholders to update KYC, bank mandates, and nominations to facilitate the claim of unpaid or unclaimed dividends and prevent their transfer to the IEPF.